Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
1(20.0%)
Phase 3
1(20.0%)
5Total
Phase 1(3)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07218146Phase 3Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Role: collaborator

NCT06885281Phase 1Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

Role: collaborator

NCT07374848Phase 1Recruiting

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Role: collaborator

NCT06179069Phase 1Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Role: collaborator

NCT06380907Phase 2Recruiting

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Role: collaborator

All 5 trials loaded